XERS News and Press, Xeris Pharmaceuticals Inc. From 07/30/20

  XP-0863 Phase 1b results and regulatory feedback support direct to Phase 3 registration study in both pediatric and adult patients with epilepsy Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and...

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that, in connection with its previously announced concurrent underwrit...

Equillium (NASDAQ: EQ ) +243%  on positive data on itolizumab in COVID-19. More news on: Equillium, Inc., WiMi Hologram Cloud Inc., Boxlight Corporation, Stocks on the move, , Read more ...

Penny Stocks That Can Be Bought For Under $4 Right Now; Are They On Your List? Whether you’re looking for penny stocks to buy or just names to add to your watchlist, the weekend is one of the best times to put in work. The markets aren’t open and it gives you time to digest all...

Last year I created a public screen on Portfolio123, a web-based subscription service that allows you to backtest screens and ranking systems. It invests in companies in the Russell 3000 that spend heavily on R&D. There were four rules in the screen, but the most important were these: ...

Some Top Penny Stocks To Watch In Early July July is already off and running. Penny stocks haven’t stutter-stepped one bit. I know some people expected that if broad sector stocks took off, stocks under $5 would lose their luster. However, that hasn’t been the case at all. Some...

YRC Worldwide (NASDAQ: YRCW ) +123%  on receiving $700M CARES act loan from U.S. Treasury. More news on: YRC Worldwide Inc., T2 Biosystems, Inc., Akero Therapeutics, Inc., Stocks on the move, , Read more ...

Xeris Pharmaceuticals (NASDAQ: XERS ) announces that Gvoke HypoPen (glucagon injection) is now available by prescription in U.S. for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above. More news on: Xeris Pharmaceuticals, Inc., Healthcare sto...

$0 copay card available for eligible commercial patients Approximately 78% of commercially insured and Medicare lives have unrestricted access to Gvoke HypoPen at launch Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation...

Xeris Pharmaceuticals (NASDAQ: XERS ) has priced its public offerings of 7.4M shares of common stock at $2.72/share for gross proceeds of ~$20.1M, and $75M of 5.00% Convertible Senior Notes due 2025. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...